Skip to content
value.today

Lipella Pharmaceuticals Inc.

Total raised
$3 M
1 round on record
Latest round
$3 M
Oct 2020
First round on record
Oct 2020
Today
Went public
See the company page

Lipella Pharmaceuticals Inc. is listed today as Lipella Pharmaceuticals Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Lipella Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2024$3 MPrivate placement after listing$2 to $10 million

Lipella Pharmaceuticals Inc.: Private sale, Dec 2024

Investors in this round

26 investors had bought by the notice of Jan 7, 2025: 26 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $6 M offered; $3 M still to sell
Smallest investment taken
$50,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$441,575
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Douglas Johnston · Executive Officer · Chief Financial Officer
  • Jonathan Kaufman · Executive Officer, Director · President, Chief Executive Officer, Secretary and Treasurer and Chairman of the Board of Directors
  • Michael Chancellor · Executive Officer, Director · Chief Medical Officer
  • Byong Kim · Director
  • Daniel Cohen · Director
  • Lori Birder · Director
  • Naoki Yoshimura · Director
  • Ryan Pruchnic · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Spartan Capital Securities, LLC (CRD 000146251) · broker-dealer Eric P. Meyer (CRD 005881743) · New York, New YorkSold in CA, CO, FL, IN, KS, MS, NJ, NM, NV, NY, OH, OK, OR, SC, TX, WI

Remarks in the notice

  • On fees: “"Spartan Capital Securities, LLC (""Spartan"") and its representative received an aggregate of 303,041 shares of Series C preferred stock and warrants to purchase up to 97,216 shares of common stock. The issuer also paid Spartan $50,000 for its legal fees."”
  • On the amounts: “Represents the maximum shares of Series B preferred stock in a best efforts private offering (subject to a $1.2 million unexercised over-allotment option), as disclosed in the issuer's Form 8-Ks filed with the SEC on December 30, 2024 and January 6, 2025.”

Signed by Jonathan Kaufman, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 7, 2025. Read the notice at the SEC.

equity, optionsSEC
Oct 2023$2 MPrivate placement after listing$2 to $10 million

Lipella Pharmaceuticals Inc.: Private sale, Oct 2023

Investors in this round

1 investor had bought by the notice of Nov 7, 2023: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$150,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Douglas Johnston · Executive Officer · Chief Financial Officer
  • Jonathan Kaufman · Executive Officer, Director · President, Chief Executive Officer, Secretary and Treasurer and Chairman of the Board of Directors
  • Michael Chancellor · Executive Officer, Director · Chief Medical Officer
  • Byong Kim · Director
  • Daniel Cohen · Director
  • Lori Birder · Director
  • Naoki Yoshimura · Director
  • Ryan Pruchnic · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in TX

Remarks in the notice

  • On fees: “In connection with the private placement, the placement agent received $150,000 and warrants to purchase up to 98,684 shares of common stock exercisable at $1.90 per share.”
  • On the amounts: “The combined effective offering price for each pre-funded common stock warrant and common stock warrant was $1.519, resulting in aggregate gross proceeds of approximately $2,000,000.”

Signed by Jonathan Kaufman, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 7, 2023. Read the notice at the SEC.

equity, optionsSEC
Oct 2020$3 MNo. 1$2 to $10 million

Lipella Pharmaceuticals Inc.: Raise no. 1, Oct 2020

Investors in this round

43 investors had bought by the notice of May 17, 2021: 43 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $4 M offered; $0 M still to sell
Smallest investment taken
$25,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$40,500
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jonathan Kaufman · Executive Officer, Director
  • David Battleman · Director
  • Michael Chancellor · Director
  • Thomas Petzinger, Jr. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • SPARTAN CAPITAL SECURITIES, LLC (CRD 146251) · New York, New YorkSold in all US states

Signed by Gabrielle Morella, Power of attorney. Source: SEC Form D and 1 amendment, newest notice filed May 17, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Lipella Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2025).

    SEC Form D · Jan 2025

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jan 2025

That is all the official record says: Lipella Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Lipella Pharmaceuticals Inc. are on record.

Investors#

No investor of Lipella Pharmaceuticals Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 43 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Lipella Pharmaceuticals Inc.
NameRoleNamed in
Douglas JohnstonChief Financial OfficerJan 2025
Jonathan KaufmanPresident, Chief Executive Officer, Secretary and Treasurer and Chairman of the Board of DirectorsJan 2025
Michael ChancellorChief Medical OfficerJan 2025
Byong KimDirectorJan 2025
Daniel CohenDirectorJan 2025
Jonathan KaufmanPresident, Chief Executive Officer, Secretary and Treasurer and Chairman of the Board of DirectorsJan 2025
Lori BirderDirectorJan 2025
Michael ChancellorChief Medical OfficerJan 2025
Naoki YoshimuraDirectorJan 2025
Ryan PruchnicDirectorJan 2025
David BattlemanDirectorMay 2021
Thomas Petzinger, Jr.DirectorMay 2021

Went public since 2022. Its SEC number is that of a company listed on a stock exchange.